Asthma

Following CHEST 2025, Hanania discusses the progress being made toward more tailored, patient-oriented care in airway disorders.

Rogers discusses the evolving definition of clinical remission in asthma and why clinicians must set higher treatment goals.

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The therapy is currently approved in almost 50 countries under the name Trimbow.

Q3 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

September 2025 saw 1 new approval, new long term data on smoking and emphysema, and more.

A meta-analysis confirmed CARATkids as a reliable tool for assessing asthma and allergic rhinitis control in children aged 6–12 years.

AstraZeneca's Airsupra gains FDA approval for mild asthma, expanding its current label.

The EXHALE-4 study evaluating the oral small molecule has met its primary endpoint of improving pre-BD FEV1.

August 2025 saw a number of novel approvals and expert perspectives for World Lung Cancer Day.

Combining salivary bacteria, serum markers, and past attack history improves risk prediction for severe asthma attacks in children.

Discover how precision medicine and advanced biologics are revolutionizing COPD and asthma management, enhancing patient outcomes and quality of life.

Clinicians explore the evolving landscape of asthma and COPD treatment, emphasizing the role of biologics and biomarkers in personalized patient care.

Experts discuss the evolving management of asthma and COPD.

New research finds patients with severe allergic asthma had greater emotional regulation than those with venom anaphylaxis, despite reporting poorer physical well-being.

Discover how recent advancements in biologic therapies transform severe asthma treatment, emphasizing personalized care and the importance of biomarker-driven decisions.

Explore the latest advancements in pulmonology, including FDA approvals and breakthrough therapies for COPD, PAH, and rare respiratory diseases.

Q2 2025 saw new therapies approved for a number of rare disease indications, multiple of which serve as the first disease-modifying therapies in the landscape.

Q2 2025 saw new therapies approved for rare rheumatological conditions and exciting research out of EULAR.

Q2 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

Discover how advancements in biologic therapies and precision medicine are transforming asthma and COPD management, enhancing patient care and outcomes.